Teva could now be in line for the world’s first launch of a biosimilar rival to Lucentis (ranibizumab), after the UK’s Medicines & Healthcare Regulatory Agency approved the Ongavia version that was developed by Bioeq and Formycon under the FYB201 designation.
UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage
Formycon-Bioeq Partnered Ongavia Receives First European Approval In UK
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
More from Biosimilars
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.